Precision Therapeutics Inc (NASDAQ:POAI)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.59 and traded as high as $0.51. Precision Therapeutics shares last traded at $0.50, with a volume of 600 shares.
The company has a current ratio of 0.12, a quick ratio of 0.08 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average price of $0.59.
Precision Therapeutics (NASDAQ:POAI) last posted its quarterly earnings data on Monday, August 19th. The medical instruments supplier reported $0.02 EPS for the quarter. The business had revenue of $0.29 million for the quarter. Precision Therapeutics had a negative net margin of 657.73% and a negative return on equity of 122.54%.
An institutional investor recently bought a new position in Precision Therapeutics stock. Vanguard Group Inc. bought a new position in Precision Therapeutics Inc (NASDAQ:POAI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned approximately 0.51% of Precision Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.85% of the company’s stock.
Precision Therapeutics Company Profile (NASDAQ:POAI)
Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.
Further Reading: What is channel trading?
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.